Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714165 | 0.81 | ESR1 (0.30) | — | |
| SCHEMBL5714336 | 0.77 | KDM4E (0.33) | ALDH1A1KMT2AKDM4ESMN1; SMN2TRPV1 | |
| SCHEMBL6328484 | 0.74 | LMNA (0.33) | ALDH1A1LMNATSHRKMT2AKDM4E | |
| SCHEMBL5713671 | 0.71 | NOTUM (0.45) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL16473875 | 0.64 | TRPV1 (0.44) | ALDH1A1KMT2ATRPV1 | |
| SCHEMBL19154878 | 0.62 | TRPV1 (0.45) | ALDH1A1KMT2ATRPV1 | |
| SCHEMBL24123617 | 0.61 | MAPT (0.45) | ALDH1A1LMNATSHRKMT2AKDM4E | |
| SCHEMBL17708030 | 0.60 | XDH (0.44) | ALDH1A1LMNATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL1450324 | 0.60 | ALDH1A1 (0.36) | ALDH1A1LMNATSHRKMT2A | |
| SCHEMBL5713764 | 0.60 | HTR1D (0.34) | ALDH1A1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | ALDH1A1 2677/4885LMNA 294/4885TSHR 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.